1.
Novel therapeutic strategies for adult obese asthmatics.
Linderholm, AL, Bratt, JM, Schuster, GU, Zeki, AA, Kenyon, NJ
Immunology and allergy clinics of North America. 2014;(4):809-23
-
-
Free full text
-
Abstract
Asthma is a complex syndrome that affects an estimated 26 million people in the United States but gaps exist in the recognition and management of asthmatic subgroups. This article proposes alternative approaches for future treatments of adult obese asthmatics who do not respond to standard controller therapies, drawing parallels between seemingly disparate therapeutics through their common signaling pathways. How metformin and statins can potentially improve airway inflammation is described and supplements are suggested. A move toward more targeted therapies for asthma subgroups is needed. These therapies address asthma and the comorbidities that accompany obesity and metabolic syndrome to provide the greatest therapeutic potential.
2.
[Cardiovascular and metabolic effects in nebulizer therapy of bronchial asthma].
Punin, AA, Bogachev, RS, Zubkov, SK, Kozyrev, OA, Khokhlova, IuA
Klinicheskaia meditsina. 2002;(1):40-3
Abstract
The aim of the study was examination of cardiovascular effects of nebulizer salbutamol (ventolin) therapy of bronchial asthma (BA). The efficiency of the drug was assessed in 38 BA patients by changes in clinical symptoms and rise of peak volume expiration rate. Before and after ventolin treatment (2.5-5 mg), measurements were made of central hemodynamics, microhemodynamics, cardiac arrhythmia, plasma electrolytes. The results of the tests indicate that nebulizer treatment with ventolin effectively and safely eliminates bronchoobstructive syndrome in BA patients. Systolic and diastolic arterial pressure, left ventricular end diastolic pressure, ventricular extrasystole declined, supraventricular extrasystole rose. Microcirculatory effects were both positive and negative. Plasma concentration of potassium ions reduced insignificantly.